Serotonin Syndrome and Neuroleptic Malignant Syndrome

1. Clinical Overview

Summary

Serotonin Syndrome (SS) and Neuroleptic Malignant Syndrome (NMS) are serious, potentially life-threatening drug-induced hyperthermic syndromes characterised by Hyperthermia, Altered Mental Status, Autonomic Instability, and Neuromuscular Abnormalities. Although they share overlapping clinical features, they have fundamentally different aetiologies, distinct neuromuscular presentations, and different time courses. [1,2,3]

Serotonin Syndrome results from Excess Serotonergic Activity at central and peripheral 5-HT receptors, typically from drug combinations (SSRI + MAOI, SSRI + Tramadol) or overdose. It presents acutely within hours (often less than 6 hours, usually less than 24 hours) and is characterised by Neuromuscular Excitability including Hyperreflexia, Clonus (Spontaneous, Inducible, Ocular), Tremor, and Myoclonus. The Hunter Serotonin Toxicity Criteria are more sensitive and specific than older diagnostic criteria. [2,4]

Neuroleptic Malignant Syndrome is an Idiosyncratic Reaction to Dopamine D2 Receptor Antagonists (Antipsychotics, Antiemetics) or Acute Dopamine Agonist Withdrawal in Parkinson's disease. It develops subacutely over days (typically 1-3 days, range 24 hours to 2 weeks), and is characterised by "Lead-Pipe" Muscular Rigidity, Bradykinesia, Extrapyramidal Features, and a slower onset. [5,6]

Early recognition is critical. The cornerstone of management for both conditions is immediate cessation of the offending drug combined with aggressive supportive care (Cooling, IV Fluids, Benzodiazepines for Agitation). Specific pharmacological treatments differ: Cyproheptadine (5-HT2A antagonist) for SS, and Dantrolene (Muscle relaxant) ± Bromocriptine/Amantadine (Dopamine agonists) for NMS. [1,2,5]

Both syndromes can lead to Rhabdomyolysis (CK often > 1,000 U/L, can exceed 100,000 U/L), Acute Kidney Injury, Disseminated Intravascular Coagulation (DIC), Multi-Organ Failure, and Death if not recognised and treated promptly. Mortality for SS is less than 5% with treatment; for NMS it is 5-10% (historically higher at 20-30% before modern intensive care). [3,5,7]

Clinical Pearls

"Hunter Criteria for Serotonin Syndrome": The Hunter Serotonin Toxicity Criteria (Sensitivity 84%, Specificity 97%) are superior to Sternbach criteria. They require a serotonergic agent PLUS one of: Spontaneous clonus, Inducible clonus + (Agitation OR Diaphoresis), Ocular clonus + (Agitation OR Diaphoresis), Tremor + Hyperreflexia, OR Hypertonia + Temperature > 38°C + (Ocular OR Inducible clonus). [4]

"Clonus = Serotonin Syndrome, Rigidity = NMS": The neuromuscular examination is key to differentiation. SS features hyperreflexia and clonus (particularly lower limbs > upper limbs). NMS features uniform lead-pipe rigidity without clonus. [2,8]

"SS is Fast (Hours), NMS is Slow (Days)": SS develops within 24 hours (most cases within 6 hours) of drug initiation or dose increase. NMS develops over 1-3 days (range 24h-14 days). This temporal pattern aids diagnosis. [2,5]

"Stop the Drug First": For both conditions, discontinuing the offending agent is the most critical initial step. Most mild-to-moderate cases of SS resolve within 24-72 hours after drug cessation. NMS may persist for 7-10 days due to prolonged dopamine receptor blockade. [1,5]

"Avoid Antipyretics": Paracetamol and NSAIDs are ineffective because hyperthermia results from muscle hyperactivity (SS) or dopamine receptor blockade in hypothalamus (NMS), not from hypothalamic resetting. Active cooling and sedation/paralysis are required. [1,8]

"MAOI Washout Period": When switching from an SSRI to an MAOI (or vice versa), a washout period is mandatory. For most SSRIs: 2 weeks. For Fluoxetine: 5 weeks (due to long half-life of active metabolite norfluoxetine). For MAOIs switching to SSRIs: 2 weeks. [9]

---

2. Epidemiology and Incidence

Serotonin Syndrome

• Incidence: Unknown true incidence due to under-recognition and misdiagnosis. Estimated at 14-16% of SSRI overdoses. Mild cases often unreported. [1,10]
• Rising Incidence: Increasing with widespread SSRI use (SSRIs are among the most prescribed medications globally). Polypharmacy increases risk. [10]
• Age: Can occur at any age. Higher risk in elderly due to polypharmacy, reduced drug clearance, and comorbidities.
• Gender: No gender predilection.
• Onset: Typically within 6 hours of drug initiation, dose increase, or addition of a second serotonergic agent. 60% of cases occur within 6 hours. [2,4]

Neuroleptic Malignant Syndrome

• Incidence: 0.01-0.02% of patients treated with antipsychotics. Higher with high-potency typical antipsychotics (Haloperidol, Fluphenazine). Lower with atypical antipsychotics but still occurs. [5,11]
• Onset: Most cases occur within 1-3 days of starting or increasing antipsychotic (or stopping dopamine agonist). Can occur up to 2 weeks after drug initiation. 40% of cases occur within 24 hours. [5]
• Age: Mean age 40 years. Can occur at any age.
• Gender: Male:Female ratio approximately 2:1. [5]
• Risk Factors: High-potency typical antipsychotics, Rapid dose escalation, IM/depot formulations, Dehydration, Agitation, Exhaustion, Organic brain disease, Hyperthyroidism, Previous episode of NMS (15-30% recurrence risk). [5,12]

---

3. Comparative Pathophysiology

Serotonin Syndrome: Excess Serotonergic Activity

Mechanism: Overstimulation of 5-HT1A and 5-HT2A receptors in the CNS (brainstem, spinal cord) and peripheral nervous system. [1,2]

5-HT1A Receptor Activation (Raphe nuclei, Hippocampus):

• Mental status changes (Confusion, Agitation)
• Anxiety, Restlessness

5-HT2A Receptor Activation (Cortex, Spinal cord, Peripheral):

• Neuromuscular effects: Hyperreflexia, Clonus, Tremor, Myoclonus (Lower limbs > Upper limbs due to greater 5-HT2A density in lumbar cord)
• Autonomic effects: Hyperthermia (from muscle hyperactivity), Tachycardia, Hypertension, Diaphoresis, Mydriasis
• GI effects: Hyperactive bowel sounds, Diarrhoea

Sources of Serotonin Excess:

1. Increased serotonin synthesis: L-tryptophan
2. Increased serotonin release: Amphetamines, Cocaine, MDMA (Ecstasy)
3. Reduced serotonin reuptake: SSRIs, SNRIs, TCAs, Tramadol, Meperidine (Pethidine)
4. Inhibition of serotonin metabolism: MAOIs (Phenelzine, Tranylcypromine, Moclobemide, Linezolid, Methylene blue)
5. Direct serotonin receptor agonism: Triptans, Buspirone, LSD
6. Increased serotonin receptor sensitivity: Lithium

Neuroleptic Malignant Syndrome: Dopamine D2 Receptor Blockade

Mechanism: Sudden and profound Dopamine D2 receptor antagonism in multiple CNS pathways. [5,6]

Hypothalamic D2 Blockade:

• Impaired thermoregulation → Hyperthermia
• Loss of hypothalamic autonomic control → Autonomic instability

Nigrostriatal Pathway D2 Blockade:

• Muscle rigidity (Lead-pipe)
• Bradykinesia, Tremor
• Extrapyramidal features

Mesocortical/Mesolimbic D2 Blockade:

• Altered mental status (Confusion, Encephalopathy, Mutism, Catatonia)

Peripheral Effects:

• Muscle rigidity → Hyperthermia (Heat generation) → Rhabdomyolysis
• Increased sympathetic outflow → Tachycardia, Labile BP

Sources of D2 Antagonism:

1. Typical antipsychotics: Haloperidol (High risk), Chlorpromazine, Fluphenazine
2. Atypical antipsychotics: Risperidone, Olanzapine, Quetiapine, Clozapine (Lower risk but still occurs)
3. Antiemetics: Metoclopramide, Prochlorperazine (D2 antagonists)
4. Dopamine depleters: Tetrabenazine, Reserpine
5. Abrupt withdrawal of dopamine agonists: Levodopa, Bromocriptine, Pramipexole (in Parkinson's disease) [13]

---

4. Detailed Comparison Table

---

5. Serotonin Syndrome: Deep Dive

5.1 Aetiology and Causative Agents

Serotonin syndrome results from therapeutic use, overdose, or drug-drug interactions involving serotonergic agents. [1,2]

Drug Classes by Mechanism

High-Risk Drug Combinations

CRITICALLY HIGH RISK:

1. SSRI + MAOI: Risk of severe SS. CONTRAINDICATED. Requires 2-week washout (5 weeks for Fluoxetine). [9]
2. SSRI + Tramadol: Common combination in pain management. Moderate-High risk. [15]
3. SSRI + Pethidine (Meperidine): High risk. Avoid combination.
4. SSRI + Linezolid: Linezolid has weak MAOI activity. Monitor closely or avoid. [16]
5. SSRI + MDMA (Ecstasy): Recreational use. Very high risk of severe SS.
6. MAOI + Sympathomimetics: Risk of hypertensive crisis AND SS.

MODERATE RISK:

1. SSRI + Triptan: Previously thought high risk, but actual risk is low. FDA warning relaxed. Still monitor. [14]
2. SSRI + St John's Wort: Over-the-counter herbal. Often not disclosed by patients.
3. SSRI + Dextromethorphan: OTC cough suppressant.
4. SSRI + Lithium: Enhances serotonergic activity.

LOW RISK:

1. SSRI + 5-HT3 Antagonists (Ondansetron): Despite theoretical concern, clinical risk appears low. [1]

5.2 Clinical Features: Hunter Serotonin Toxicity Criteria

The Hunter Criteria (2003) are the most validated diagnostic criteria for SS (Sensitivity 84%, Specificity 97%). They outperform the older Sternbach criteria. [4]

Hunter Criteria

In the presence of a serotonergic agent, diagnosis requires ONE of the following:

1. Spontaneous Clonus
2. Inducible Clonus AND (Agitation OR Diaphoresis)
3. Ocular Clonus AND (Agitation OR Diaphoresis)
4. Tremor AND Hyperreflexia
5. Hypertonia AND Temperature > 38°C AND (Ocular Clonus OR Inducible Clonus)

Clinical Features by System

Neuromuscular (Most Specific):

• Clonus: Rhythmic, involuntary muscular contractions. KEY FINDING.
  • "Inducible clonus: Elicited by rapid dorsiflexion of ankle (Lower limbs > Upper limbs)"
  • "Spontaneous clonus: Occurs without provocation"
  • "Ocular clonus: Slow, continuous, horizontal eye movements (distinct from nystagmus)"
• Hyperreflexia: Increased deep tendon reflexes. More pronounced in lower limbs.
• Myoclonus: Brief, shock-like muscle jerks
• Tremor: Fine, rapid tremor
• Lower Limb Predominance: Reflects greater 5-HT2A receptor density in lumbar spinal cord

Mental Status:

• Agitation, Restlessness
• Confusion, Delirium
• Hypervigilance
• Anxiety
• Less common: Seizures (severe cases)

Autonomic:

• Hyperthermia: Mild-moderate (38-40°C). Severe cases > 40°C (associated with worse outcomes)
• Tachycardia: Common
• Hypertension: Variable
• Diaphoresis: Profuse sweating
• Mydriasis: Dilated pupils
• Hyperactive bowel sounds
• Diarrhoea
• Flushed, warm skin

Severity Classification:

• Mild: Tachycardia, Diaphoresis, Hyperreflexia, Mydriasis, Anxiety. Temperature less than 38°C.
• Moderate: Temperature 38-40°C, Horizontal ocular clonus, Agitation, Hyperactive bowel sounds, Inducible clonus.
• Severe: Temperature > 40°C, Delirium, Muscular rigidity (severe cases), Seizures, Rhabdomyolysis, Metabolic acidosis, DIC, Renal failure. [8]

5.3 Investigations

Serotonin syndrome is a CLINICAL diagnosis. No specific diagnostic test exists.

Purpose of investigations:

1. Exclude alternative diagnoses (Sepsis, Meningitis, Encephalitis, Anticholinergic toxicity, Sympathomimetic toxicity)
2. Identify complications (Rhabdomyolysis, AKI, DIC)
3. Guide supportive management

Initial Investigations:

• Full Blood Count: WBC usually normal or mildly elevated (cf. leucocytosis in NMS)
• CK: Normal or mildly elevated (less than 1,000 U/L in mild-moderate cases). Significantly elevated (> 1,000) in severe cases with rigidity
• Renal Function (Urea, Creatinine, Electrolytes): Monitor for AKI secondary to rhabdomyolysis
• LFTs: May be mildly elevated
• Blood Gas: Metabolic acidosis in severe cases
• Coagulation Screen: Monitor for DIC
• Urinalysis: Myoglobinuria (tea-coloured urine) if rhabdomyolysis
• Drug Levels: Paracetamol, Salicylate (if overdose suspected). Serotonin levels NOT useful.

Imaging:

• CT Head: If altered mental status with unclear cause. Exclude intracranial pathology.
• Lumbar Puncture: If meningitis/encephalitis cannot be excluded clinically

ECG: Tachycardia, Sinus tachycardia. Rule out arrhythmias.

5.4 Differential Diagnosis

Key Differentials:

1. Neuroleptic Malignant Syndrome: See comparison table. Key: Rigidity (NMS) vs Clonus (SS), Slow onset (NMS) vs Rapid (SS).
2. Anticholinergic Toxicity: "Dry as a bone, Red as a beet, Hot as a hare, Blind as a bat, Mad as a hatter". Features: Dry skin (No diaphoresis), Decreased bowel sounds, Urinary retention, Mydriasis, Hyperthermia, Confusion. Caused by: Antihistamines, TCAs, Atropine, Benztropine. [8]
3. Sympathomimetic Toxicity: Cocaine, Amphetamines. Features: Agitation, Tachycardia, Hypertension, Hyperthermia, Mydriasis, Diaphoresis. Key: Absence of clonus and hyperreflexia.
4. Malignant Hyperthermia: Rare genetic disorder triggered by volatile anaesthetics (Sevoflurane, Isoflurane) or Succinylcholine. Features: Severe hyperthermia (Can reach > 44°C), Muscle rigidity, Masseter spasm, Very high CK (> 20,000). Treatment: Dantrolene. [17]
5. Meningitis/Encephalitis: Fever, Confusion, Headache, Neck stiffness, Photophobia. CSF analysis diagnostic.
6. Sepsis: Systemic infection. Features: Fever, Tachycardia, Hypotension, Elevated WBC, Positive cultures. No clonus.
7. Thyrotoxicosis/Thyroid Storm: Hyperthermia, Tachycardia, Agitation, Tremor. Key: No clonus. Check TFTs.
8. Alcohol/Benzodiazepine Withdrawal: Tremor, Tachycardia, Hypertension, Agitation, Seizures. Key: Withdrawal history, No hyperthermia (usually), No clonus.
9. Strychnine Poisoning: Rare. Muscle spasms, Opisthotonus. No autonomic features.

"Clonus Clinches It": In a patient on serotonergic drugs, the presence of clonus (especially inducible or spontaneous) strongly suggests SS over other differentials. [2,4]

5.5 Management of Serotonin Syndrome

Management is supportive with specific antidote (Cyproheptadine) for moderate-severe cases. [1,2,8]

Step 1: IMMEDIATE – Stop All Serotonergic Agents

• Discontinue ALL serotonergic drugs immediately. Most cases improve within 24 hours of cessation.
• Do NOT restart without careful consideration and specialist input.
• For Fluoxetine: Expect longer resolution time (1-2 weeks) due to long half-life.

Step 2: SUPPORTIVE CARE

A. Resuscitation (ABCDE Approach):

• Airway: Secure if GCS less than 8 or unable to protect airway
• Breathing: Supplemental oxygen. Monitor SpO2. May require intubation if severe
• Circulation: IV access. Fluid resuscitation. Cardiac monitoring.
• Disability: GCS assessment. Blood glucose.
• Exposure: Check temperature. Active cooling if hyperthermia.

B. Monitoring:

• HDU/ICU for moderate-severe cases
• Continuous cardiac monitoring, Pulse oximetry
• Hourly temperature, BP, HR
• Urine output monitoring (Rhabdomyolysis risk)
• Serial CK, Renal function, Electrolytes

C. Temperature Control (CRITICAL if T≥39.5°C):

• Active cooling: Ice packs to groin/axillae, Cooling blankets, Evaporative cooling, Cold IV fluids
• Avoid antipyretics (Paracetamol, NSAIDs): Ineffective. Hyperthermia is due to muscle hyperactivity, not hypothalamic resetting.
• Consider intubation + Paralysis: For severe hyperthermia (> 40°C) or rigidity unresponsive to sedation
  • Use non-depolarising neuromuscular blockers (Rocuronium, Vecuronium)
  • AVOID Succinylcholine (Risk of hyperkalaemia with rhabdomyolysis, Risk of malignant hyperthermia)
  • Paralysis abolishes muscle-generated heat → Rapid temperature reduction
  • Requires mechanical ventilation

D. Sedation and Agitation Control:

• Benzodiazepines: First-line for agitation, tremor, myoclonus
  • Diazepam 5-10mg IV, repeat as needed
  • Lorazepam 1-2mg IV/IM
  • Midazolam 2.5-5mg IV (ICU setting)
• Avoid physical restraints: Worsen hyperthermia and rhabdomyolysis
• Avoid antipsychotics: May worsen condition or precipitate NMS

E. Fluid Resuscitation:

• Aggressive IV fluids (Crystalloids: Normal saline, Hartmann's)
• Prevent rhabdomyolysis-induced AKI
• Target urine output > 1-2 ml/kg/h
• Monitor for fluid overload

F. Autonomic Instability Management:

• Hypertension: Short-acting agents (Esmolol, Nitroprusside). Avoid beta-blockers alone (unopposed alpha-stimulation risk).
• Hypotension: Fluids first. If refractory, direct-acting vasopressors (Noradrenaline preferred).
• Tachycardia: Usually responds to sedation and temperature control.

Step 3: SPECIFIC ANTIDOTE – Cyproheptadine

Cyproheptadine is a 5-HT2A antagonist (also antihistamine). [1,2]

Indications:

• Moderate-to-severe SS
• Persistent symptoms despite supportive care
• Temperature > 39°C with neuromuscular features

Dosing:

• Loading dose: 12 mg PO/NG
• Maintenance: 2 mg every 2 hours until symptoms improve
• Maximum: 32 mg/24 hours
• Once improved, taper to: 8 mg every 6 hours for 24 hours

Limitations:

• Only available orally or via NG tube (No IV formulation)
• Sedating (Can complicate mental status assessment)
• Evidence base is limited (Case reports, small case series). No RCTs.

Alternative (If cyproheptadine unavailable):

• Chlorpromazine: 5-HT2A antagonist. Dose: 25-50 mg IM. CAUTION: Risk of hypotension, Can precipitate NMS, Limited evidence. [2]

Step 4: MANAGE COMPLICATIONS

Rhabdomyolysis:

• Aggressive IV fluids
• Monitor CK (Peak usually 24-72h), Renal function, Potassium, Phosphate, Calcium
• Target urine output > 200 ml/h
• Consider urinary alkalinisation (Controversial): Sodium bicarbonate to maintain urine pH > 6.5
• Renal Replacement Therapy (RRT) if refractory AKI or severe electrolyte disturbance

Seizures:

• Benzodiazepines: Lorazepam 4mg IV, Diazepam 10mg IV
• Consider intubation if refractory

DIC:

• Supportive care
• Correct coagulopathy: FFP, Platelets, Cryoprecipitate as needed

ARDS/Respiratory Failure:

• Mechanical ventilation
• Lung-protective ventilation strategies

Step 5: DISPOSITION

• Mild cases (Tachycardia, Diaphoresis, Hyperreflexia only): Observation 6-12 hours. Discharge if symptoms resolve.
• Moderate-to-severe cases: Admit to HDU/ICU. Monitor 24-48 hours after resolution.
• Patient education: Explain drug interaction. Provide information on serotonergic drugs to avoid.
• Follow-up: Psychiatry/Pain clinic review for medication adjustment.

5.6 Prognosis

• Duration: Most cases resolve 24-72 hours after drug cessation. Fluoxetine: 1-2 weeks (long half-life of norfluoxetine).
• Mortality: less than 5% with early recognition and treatment. Higher in severe cases with hyperthermia > 40°C.
• Morbidity: Risk of permanent neurological sequelae if prolonged hyperthermia (> 40°C for > 6 hours).
• Recurrence: Can recur if serotonergic drug reintroduced. Avoid causative combination.

---

6. Neuroleptic Malignant Syndrome: Deep Dive

6.1 Aetiology and Causative Agents

NMS is an idiosyncratic reaction to dopamine D2 receptor antagonists or dopamine agonist withdrawal. It is NOT dose-dependent but risk increases with higher doses and rapid escalation. [5,6]

Causative Agents

Risk Factors for NMS [5,12]

Medication-Related:

• High-potency typical antipsychotics (Haloperidol > Chlorpromazine)
• Rapid dose escalation
• IM or depot administration (Higher plasma levels, Prolonged effect)
• Polypharmacy (Multiple antipsychotics, Lithium + antipsychotic)
• Recent antipsychotic switch

Patient-Related:

• Dehydration
• Agitation, Exhaustion
• Male gender (2:1 ratio)
• Organic brain disease (Dementia, Encephalitis, Brain injury)
• Hyperthyroidism
• Iron deficiency (Low serum iron associated with NMS)
• Previous episode of NMS (15-30% recurrence risk if antipsychotic reintroduced)

6.2 Clinical Features

NMS presents as a tetrad: Hyperthermia, Rigidity, Altered Mental Status, Autonomic Instability. [5,6]

Neuromuscular (Cardinal Feature):

• "Lead-Pipe" Rigidity: Generalised, Uniform muscle rigidity throughout range of motion
  • Severe and sustained
  • Affects ALL muscle groups (Limbs, Trunk, Jaw)
  • May have superimposed cogwheel rigidity
• Bradykinesia, Akinesia
• Tremor (Parkinsonian tremor, not myoclonus)
• Dysarthria, Dysphagia (Risk of aspiration)
• Opisthotonus (Severe cases)
• Reflexes: Normal or decreased (Masked by rigidity)
• NO clonus (Key difference from SS)

Mental Status:

• Encephalopathy (Confusion, Disorientation)
• Stupor, Mutism
• Catatonia (Waxy flexibility, Posturing)
• Fluctuating consciousness
• Seizures (Less common than SS)

Autonomic Instability:

• Hyperthermia: Often > 40°C (Can reach 42-43°C). Sustained.
• Tachycardia: Severe (HR > 120 bpm common)
• Labile Blood Pressure: Hypertension OR Hypotension (fluctuating)
• Tachypnoea
• Diaphoresis: Profuse sweating
• Pallor (vs Flushed skin in SS)
• Sialorrhoea (Drooling)
• Urinary incontinence

Onset and Progression:

• Typically develops over 1-3 days (Range: 24 hours to 2 weeks)
• 40% occur within first 24 hours of antipsychotic initiation
• 66% within first week
• 96% within 30 days
• Can occur at any point during treatment, even after years of stable therapy

6.3 Investigations

NMS is a clinical diagnosis. Investigations confirm findings and exclude differentials.

Blood Tests:

• CK: Markedly elevated in > 95% of cases
  • Usually > 1,000 U/L
  • Often > 10,000 U/L
  • Can exceed 100,000 U/L
  • "Peak: 2-5 days after onset"
  • Returns to normal over 1-2 weeks
• FBC: Leucocytosis (WBC 10,000-40,000). Left shift.
• LFTs: Elevated LDH, AST, ALT (From muscle breakdown)
• Renal Function: Elevated creatinine, Urea (AKI from rhabdomyolysis)
• Electrolytes: Hyperkalaemia, Hyperphosphataemia, Hypocalcaemia (Rhabdomyolysis)
• Serum Iron: Low serum iron (May be pathophysiologically relevant)
• Blood Gas: Metabolic acidosis (Lactic acidosis)
• Coagulation: Monitor for DIC

Urinalysis:

• Myoglobinuria (Positive for blood on dipstick without RBCs on microscopy)

Lumbar Puncture:

• CSF: Normal (Excludes meningitis/encephalitis)

Neuroimaging:

• CT/MRI Head: Usually normal. Excludes structural lesions, Stroke, Haemorrhage.

EEG:

• Generalised slowing (Non-specific)

EMG:

• Increased muscle activity (Not routinely done)

6.4 Diagnostic Criteria

No universally accepted criteria. Diagnosis is clinical based on constellation of features.

DSM-5 Criteria (Research purposes):

• Severe muscle rigidity AND elevated temperature
• Associated with use of antipsychotic medication
• Plus TWO or more of:
  • Diaphoresis
  • Dysphagia
  • Tremor
  • Incontinence
  • Altered consciousness (Confusion to coma)
  • Mutism
  • Tachycardia
  • Elevated or labile BP
  • Leucocytosis
  • Elevated CK
• Symptoms not due to another substance, medical condition, or psychiatric disorder

Practical Clinical Approach:

• History of antipsychotic use (or dopamine agonist withdrawal)
• Hyperthermia (Usually > 40°C)
• Lead-pipe rigidity
• Altered mental status
• Elevated CK (Usually > 1,000)
• Exclusion of other causes (Sepsis, CNS infection, Malignant hyperthermia, SS)

6.5 Differential Diagnosis

Key Differentials:

1. Serotonin Syndrome: See comparison table. Key: Clonus (SS) vs Rigidity (NMS), Rapid onset (SS) vs Slow (NMS), Lower CK (SS) vs Very high CK (NMS).
2. Malignant Hyperthermia: Genetic disorder. Triggered by volatile anaesthetics (Sevoflurane) or Succinylcholine. Features: Very rapid onset (Intraoperatively), Masseter spasm, Very high CK (> 20,000), Severe acidosis. Treatment: Dantrolene. Family history may be present. [17]
3. Malignant Catatonia: Idiopathic or associated with psychiatric illness. Features: Catatonia (Waxy flexibility, Posturing, Mutism), Autonomic instability, Hyperthermia. Key: No antipsychotic exposure. Treatment: Benzodiazepines, ECT. May be indistinguishable from NMS (Some consider them on a spectrum). [18]
4. Sepsis/CNS Infection: Fever, Altered consciousness, Rigidity (Meningism). Key: CSF abnormalities, Positive cultures, Source of infection. CK usually normal/mildly elevated.
5. Non-Convulsive Status Epilepticus: Altered consciousness, Autonomic changes. Diagnosis: EEG (Seizure activity). CK normal.
6. Heatstroke: Environmental exposure. Very high temperature (> 40°C). Key: Environmental history, Absence of rigidity, Hot, dry skin (Classic heatstroke) or Sweating (Exertional heatstroke).
7. Thyroid Storm: Hyperthyroidism. Features: Hyperthermia, Tachycardia, Agitation. Key: No rigidity, Elevated T4/T3, Suppressed TSH.
8. Anticholinergic Toxicity: Hyperthermia, Delirium, Mydriasis. Key: Dry skin (No sweating), Decreased bowel sounds, No rigidity.
9. Central Nervous System Infection (Encephalitis, Brain Abscess): Fever, Confusion, Focal neurology. Imaging and CSF diagnostic.
10. Parkinsonism-Hyperpyrexia Syndrome: Dopamine agonist withdrawal in Parkinson's. Clinically identical to NMS. Treatment: Reinstate dopamine agonist. [13]

"Low Serum Iron": May help differentiate NMS from other hyperthermic syndromes (Low in NMS, Normal in others). Not routinely used. [5]

6.6 Management of Neuroleptic Malignant Syndrome

Management is primarily supportive with specific treatments (Dantrolene, Bromocriptine) for severe cases. [5,6]

Step 1: IMMEDIATE – Stop Causative Agent

• Discontinue ALL antipsychotics immediately
• Exception: If NMS due to dopamine agonist withdrawal (Parkinson's disease) → REINSTATE dopamine agonist (Levodopa, Bromocriptine) [13]
• Do NOT restart antipsychotic for at least 2 weeks (Ideally longer)
• When restarting antipsychotic (if essential):
  • Wait at least 2 weeks (Preferably 1 month)
  • Use lowest possible dose of lower-risk atypical (Quetiapine, Clozapine)
  • Gradual titration
  • Close monitoring

Step 2: SUPPORTIVE CARE (ICU/HDU)

A. Resuscitation:

• Airway: High risk of aspiration (Dysphagia, Decreased consciousness). Early intubation if GCS less than 8.
• Breathing: Supplemental oxygen. Mechanical ventilation often required.
• Circulation: Large-bore IV access. Aggressive fluid resuscitation (3-4 L/day). Central line for vasopressors if needed.
• Monitoring: Continuous cardiac monitoring, Pulse oximetry, Hourly vitals, Strict input-output monitoring

B. Temperature Control (CRITICAL):

• Active cooling: Ice packs, Cooling blankets, Evaporative cooling, Cold IV fluids
• Target: Temperature less than 38.5°C
• Avoid antipyretics: Ineffective
• Intubation + Paralysis: For refractory hyperthermia
  • Non-depolarising NMB (Rocuronium, Vecuronium)
  • AVOID Succinylcholine (Risk of hyperkalaemia, Malignant hyperthermia)

C. Fluid Resuscitation (Rhabdomyolysis Prevention):

• Aggressive IV crystalloids: 3-4 L/day (or more)
• Target urine output: > 150-200 ml/h
• Monitor: Urine colour (Myoglobinuria = Tea-coloured), Fluid balance
• Urinary alkalinisation (Controversial): Sodium bicarbonate to maintain urine pH > 6.5

D. Sedation:

• Benzodiazepines for agitation
  • Lorazepam 1-2mg IV/IM every 4-6 hours
  • Diazepam 5-10mg IV as needed

E. Autonomic Instability:

• Labile BP: Support with fluids, Vasopressors (Noradrenaline) if hypotensive, Short-acting antihypertensives if severe hypertension
• Tachycardia: Usually improves with temperature control and sedation

F. Prevent Aspiration:

• NBM (Nil by mouth)
• NG tube for decompression if ileus
• Elevate head of bed

G. DVT Prophylaxis:

• Immobility is significant risk factor
• Low molecular weight heparin (LMWH) unless contraindicated
• Pneumatic compression devices

Step 3: SPECIFIC PHARMACOLOGICAL TREATMENTS

Evidence for specific treatments is limited (Case series, retrospective reviews). No RCTs.

A. Dantrolene [5,6,19]

Mechanism: Muscle relaxant. Inhibits ryanodine receptors on sarcoplasmic reticulum → Reduces intracellular calcium release → Reduces muscle contraction.

Indications:

• Severe NMS with hyperthermia > 40°C and marked rigidity
• Refractory hyperthermia despite cooling

Dosing:

• Initial: 1-2.5 mg/kg IV bolus over 10 minutes
• Repeat: Every 5-10 minutes as needed
• Maximum: 10 mg/kg/day
• Maintenance (if response): 0.25 mg/kg IV every 6 hours for 24-48 hours, then taper

Evidence:

• Efficacy: Mixed evidence. Some studies show benefit (Reduced mortality, Faster recovery). Others show no significant benefit over supportive care alone.
• Rapid temperature reduction and reduction in rigidity often observed.
• More effective in Malignant Hyperthermia (where it is first-line). Effectiveness in NMS less certain.

Side Effects:

• Muscle weakness (Expected)
• Hepatotoxicity (Monitor LFTs, especially if prolonged use)
• Respiratory depression
• Thrombophlebitis

Practical Use:

• Consider in severe cases
• Early use may improve outcomes
• Monitor carefully for respiratory depression

B. Bromocriptine (Dopamine Agonist) [5,6]

Mechanism: Dopamine D2 receptor agonist. Restores dopaminergic tone.

Indications:

• Adjunct to supportive care
• May speed recovery

Dosing:

• Initial: 2.5 mg PO/NG three times daily
• Titrate: Increase to 5-10 mg every 8 hours as tolerated
• Maximum: 45 mg/day
• Duration: Continue for 10 days after resolution, then taper over 1-2 weeks (Risk of relapse if stopped abruptly)

Evidence:

• Limited. Case series suggest benefit (Faster recovery, Reduced rigidity).
• May reduce duration of NMS.

Side Effects:

• Nausea, Vomiting (Common)
• Hypotension (Risk of worsening autonomic instability)
• Hallucinations, Confusion (May complicate mental status assessment)
• Contraindicated if NMS precipitated by dopamine agonist withdrawal (Paradoxical)

Alternative Dopamine Agonist:

• Amantadine: 100-200 mg PO/NG twice daily. Similar mechanism. May be better tolerated.

C. Combined Therapy: Dantrolene + Bromocriptine

• Some clinicians use both for severe NMS.
• Rationale: Dantrolene (Peripheral muscle relaxation) + Bromocriptine (Central dopaminergic restoration).
• Evidence is anecdotal.

Step 4: ELECTROCONVULSIVE THERAPY (ECT)

Indications:

• Refractory NMS (Not responding to supportive care + pharmacotherapy)
• Malignant Catatonia (Which may be indistinguishable from NMS)

Evidence: [18,20]

• Multiple case reports and case series show efficacy.
• Safe in NMS (despite concerns).
• Rapid improvement in mental status, rigidity, and autonomic features.

Mechanism:

• Unknown. May reset dysregulated dopaminergic pathways.

Practical Use:

• Consider early in severe/refractory cases (Within 48-72 hours if not improving).
• Liaise with psychiatry.
• Requires anaesthesia (Use non-depolarising NMB, Avoid Succinylcholine).

Step 5: MANAGE COMPLICATIONS

Rhabdomyolysis and AKI:

• As per SS management (See Section 5.5)
• Aggressive fluids (Most important intervention)
• Monitor CK, Electrolytes, Renal function
• Renal Replacement Therapy if AKI refractory or severe hyperkalaemia

Respiratory Failure:

• Common (Chest wall rigidity, Aspiration pneumonia, ARDS)
• Mechanical ventilation
• Aspiration precautions

DIC:

• Supportive care
• Blood product replacement (FFP, Platelets, Cryoprecipitate)

Thromboembolic Complications:

• High risk (Immobility, Dehydration, Hypercoagulability)
• DVT/PE prophylaxis (LMWH)
• Compression stockings

Cardiac Arrhythmias:

• Continuous monitoring
• Correct electrolyte abnormalities (Hypokalaemia, Hypomagnesaemia)

Step 6: DISPOSITION AND LONG-TERM MANAGEMENT

Acute Phase:

• ICU/HDU admission for all moderate-severe cases
• Duration: Typically 7-10 days (Longer with depot antipsychotics: weeks to months)

Recovery Phase:

• Gradual resolution over days to weeks
• CK normalisation may lag clinical recovery
• Monitor for relapse if antipsychotic reintroduced too early

Follow-Up:

• Psychiatry review: Discuss alternative treatment strategies (Non-dopamine antagonist medications, ECT, CBT)
• Patient education: Explain NMS. Provide alert card/bracelet.
• Family counselling: Genetic component possible (Rare familial cases reported).

If Antipsychotic Required Again:

• Wait at least 2 weeks (Preferably 4-6 weeks)
• Re-challenge risk: 15-30% recurrence rate
• Choose low-risk agent: Atypical antipsychotic (Quetiapine, Clozapine preferred)
• Start low, go slow: Lowest effective dose, Gradual titration
• Close monitoring: Outpatient review every 1-2 weeks initially
• Avoid high-risk agents: Haloperidol, Fluphenazine, Depot formulations

6.7 Prognosis

• Duration: Mean 7-10 days with treatment. Range 2-30 days. Longer with depot antipsychotics (Up to weeks or months). [5]
• Mortality: 5-10% with modern intensive care (Previously 20-30% before ICU care). Mortality higher with:
  • Temperature > 40°C
  • CK > 15,000 U/L
  • Acute renal failure
  • Delayed diagnosis
• Morbidity: Sequelae in up to 4% of survivors:
  • Persistent neurological deficits (Parkinsonism, Cognitive impairment, Cerebellar signs)
  • Renal impairment
  • Usually improve over months
• Full recovery: Most patients (> 90%) recover completely with appropriate treatment.
• Recurrence: 15-30% if antipsychotic reintroduced (Especially if same agent or too early). [5]

---

7. Key Clinical Scenarios and Pitfalls

Scenario 1: SSRI + Tramadol (Common in Primary Care)

Case: 65-year-old on Sertraline 100mg for depression. Started Tramadol 50mg QDS for chronic back pain. Presents to ED 8 hours later with agitation, tremor, diaphoresis.

Pitfall: Tramadol is an SNRI (in addition to opioid agonist). High risk with SSRIs. [15]

Action:

• Stop Tramadol immediately
• Check for clonus (Inducible ankle clonus likely present)
• Diagnosis: Serotonin Syndrome (Hunter criteria met)
• Management: Supportive care, Benzodiazepines for agitation, Observe 12-24 hours
• Alternative analgesia: Paracetamol, NSAIDs, Non-serotonergic opioids (Morphine, Oxycodone)

Scenario 2: Linezolid + SSRI (Hospital Inpatient)

Case: Patient on Citalopram 20mg for anxiety. Admitted with pneumonia. Started on Linezolid (MRSA cover). Day 3: Confusion, fever 38.5°C, tremor.

Pitfall: Linezolid is a weak, non-selective MAOI. Risk of SS with SSRIs. [16]

Action:

• Stop Linezolid (Switch to alternative antibiotic: Vancomycin)
• Assess for clonus
• Management: Supportive care
• FDA Warning: Avoid Linezolid + SSRIs/SNRIs unless benefits outweigh risks and close monitoring possible.

Scenario 3: MAOI Washout Failure

Case: Patient switched from Fluoxetine to Phenelzine (MAOI) for treatment-resistant depression. Psychiatrist advised 2-week washout. Patient develops severe SS.

Pitfall: Fluoxetine has a long half-life (4-6 days). Active metabolite norfluoxetine has half-life of 4-16 days. Requires 5-week washout, not 2 weeks. [9]

Action:

• Know drug half-lives: Fluoxetine = 5 weeks. Other SSRIs = 2 weeks.
• Educate prescribers.

Scenario 4: "Sepsis" Misdiagnosis

Case: Young adult on Venlafaxine recently increased from 75mg to 150mg. Presents with fever 39°C, confusion, tachycardia, rigidity. Diagnosed with "sepsis". Treated with antibiotics and antipsychotics for agitation. Deteriorates.

Pitfall: SS misdiagnosed as sepsis. Administration of antipsychotic (Haloperidol) → Risk of worsening or precipitating NMS. [8]

Action:

• Always consider drug-induced causes in fever + altered mental status
• Check medication history (Recent changes?)
• Examine for neuromuscular signs (Clonus, Hyperreflexia, Rigidity)
• Avoid antipsychotics in unclear agitation with fever

Scenario 5: NMS from Metoclopramide (Antiemetic)

Case: Elderly patient with gastroparesis on Metoclopramide 10mg TDS for 6 months. Presents with confusion, fever 40.5°C, rigidity, incontinence.

Pitfall: Metoclopramide is a D2 antagonist. Often overlooked as cause of NMS (Perceived as "just an antiemetic"). [5]

Action:

• Consider ALL dopamine antagonists (including antiemetics) as potential NMS triggers
• Metoclopramide, Prochlorperazine, Domperidone all carry risk
• Alternative antiemetics: Ondansetron (5-HT3 antagonist), Cyclizine (Antihistamine)

Scenario 6: Parkinson's Disease – Dopamine Agonist Withdrawal

Case: Parkinson's patient admitted for surgery. Levodopa held NPO. Day 2: High fever, rigidity worse than baseline, confusion.

Pitfall: Abrupt dopamine agonist withdrawal → Parkinsonism-Hyperpyrexia Syndrome (clinically identical to NMS). [13]

Action:

• NEVER abruptly stop dopamine agonists in Parkinson's
• If NBM: Consider NG tube or transdermal rotigotine patch to continue therapy
• If syndrome develops: REINSTATE dopamine agonist (Not stop, as in typical NMS)

---

8. Evidence Summary and Guidelines

Key Evidence

Serotonin Syndrome:

1. Boyer & Shannon (2005): Landmark review in NEJM. Comprehensive overview of SS pathophysiology, diagnosis, management. [1]
2. Dunkley et al (2003): Development and validation of Hunter Serotonin Toxicity Criteria (Sensitivity 84%, Specificity 97%). More accurate than Sternbach criteria. [4]
3. Mikkelsen et al (2023): Recent focused review emphasising pharmacological context and early recognition. [10]

Neuroleptic Malignant Syndrome:

1. Strawn et al (2007): Comprehensive review of NMS epidemiology, clinical features, management. [5]
2. Perry & Wilborn (2012): Direct comparison of SS and NMS. Emphasis on differential diagnosis and laboratory differentiation. [8]
3. Reulbach et al (2007): Large case series analysing mortality and risk factors in NMS. [7]

Pharmacological Treatments:

1. Cyproheptadine: Evidence limited to case reports and case series. No RCTs. [1,2]
2. Dantrolene for NMS: Mixed evidence. Some studies show benefit, others no difference vs supportive care. Meta-analysis limited by heterogeneity. [19]
3. Bromocriptine for NMS: Case series suggest benefit. No RCTs. [5,6]
4. ECT for refractory NMS: Multiple case reports and case series show efficacy. Considered safe and effective. [18,20]

Clinical Guidelines

No specific international guidelines exist for SS or NMS. Management based on:

• Expert consensus
• Case series and retrospective reviews
• Extrapolation from related conditions (Malignant hyperthermia, Heatstroke)

Principles (Consensus):

1. Early recognition (Clinical diagnosis)
2. Immediate cessation of causative drug
3. Aggressive supportive care (Fluids, Cooling, Sedation)
4. ICU/HDU care for moderate-severe cases
5. Specific treatments (Cyproheptadine for SS, Dantrolene/Bromocriptine for NMS) for severe cases
6. Long washout period before reintroduction of offending drug class

---

9. Prevention Strategies

For Serotonin Syndrome

1. Medication Reconciliation:

• Always check current medications before prescribing serotonergic drugs
• Use electronic prescribing systems with drug-drug interaction alerts

2. Patient Education:

• Warn patients on SSRIs about OTC serotonergic drugs (Dextromethorphan, St John's Wort)
• Advise to inform all prescribers (GP, Dentist, ED) about SSRI use

3. Safe Prescribing Practices:

• Avoid high-risk combinations (SSRI + MAOI, SSRI + Pethidine)
• MAOI washout: 2 weeks for most SSRIs, 5 weeks for Fluoxetine
• Start low, go slow when initiating or switching serotonergic drugs
• Monotherapy preferred (Avoid polypharmacy)

4. Special Populations:

• Elderly: Higher risk due to polypharmacy and reduced drug clearance. Use lower doses.
• Renal/Hepatic impairment: Reduced drug clearance. Dose adjust.

5. Alternative Analgesia:

• For patients on SSRIs requiring analgesia: Avoid Tramadol and Pethidine. Use: Paracetamol, NSAIDs, Morphine, Oxycodone.

For Neuroleptic Malignant Syndrome

1. Antipsychotic Prescribing:

• Use lowest effective dose
• Gradual titration (Avoid rapid escalation)
• Prefer atypical antipsychotics over typical (Lower risk, though not zero)
• Avoid depot formulations initially (If NMS occurs, prolonged duration)

2. Identify High-Risk Patients:

• Previous NMS (15-30% recurrence)
• Dehydration, Exhaustion, Organic brain disease
• Increase monitoring in these patients

3. Monitoring:

• Regular clinical assessment in first weeks after starting/increasing antipsychotic
• Temperature monitoring if patient becomes acutely unwell
• Early detection of prodromal features (Rigidity, Fever)

4. Hydration:

• Ensure adequate hydration in patients on antipsychotics (Especially in hot weather, During illness)

5. Parkinson's Disease:

• Never abruptly stop dopamine agonists
• Bridging strategies if NBM (NG tube, Transdermal rotigotine)

6. Antiemetic Choice:

• Avoid D2 antagonists (Metoclopramide, Prochlorperazine) long-term or in high-risk patients
• Alternatives: Ondansetron, Cyclizine, Domperidone (lower CNS penetration)

---

10. Special Populations

Elderly

Increased Risk:

• Polypharmacy (Higher risk of drug interactions)
• Reduced drug clearance (Renal/hepatic impairment)
• Multiple comorbidities

Management Considerations:

• Lower threshold for admission and monitoring
• Start low, go slow with all psychotropic medications
• Careful medication reconciliation

Pregnancy and Breastfeeding

SS in Pregnancy: [21]

• SSRIs commonly used in pregnancy for depression/anxiety
• Risk of SS if drug interactions occur
• Management: As per standard SS management. Supportive care is safe in pregnancy.
• Cyproheptadine: Limited data in pregnancy. Use if benefits outweigh risks.

NMS in Pregnancy:

• Rare (Antipsychotics less commonly used in pregnancy)
• High maternal and fetal risk (Hyperthermia, rhabdomyolysis)
• Management: Supportive care. Dantrolene: Category C (Animal studies show harm, but may be used if life-threatening).

Neonatal Serotonin Syndrome:

• Neonates exposed to SSRIs in utero may develop withdrawal or serotonin toxicity in first days of life
• Features: Jitteriness, Tremor, Hypertonia, Feeding difficulties
• Usually mild and self-limiting

Paediatrics

SS in Children/Adolescents:

• Increasing incidence due to rising SSRI use for depression/anxiety
• Clinical features similar to adults
• Management: Supportive care (Paediatric ICU if severe)

NMS in Children:

• Less common (Antipsychotics less prescribed)
• Higher mortality historically (Improved with modern care)

---

11. Complications (Detailed)

Rhabdomyolysis

Mechanism: Muscle hyperactivity (SS) or Rigidity (NMS) → Muscle breakdown → Myoglobin release

Features:

• Elevated CK: > 1,000 U/L (Moderate), > 10,000 (Severe), > 100,000 (Life-threatening)
• Myoglobinuria: Tea-coloured urine
• Muscle pain (Though may be masked in altered consciousness)

Complications:

• Acute Kidney Injury: Myoglobin deposition in renal tubules → Tubular necrosis
• Electrolyte Disturbance: Hyperkalaemia (From muscle breakdown, Life-threatening arrhythmia risk), Hyperphosphataemia, Hypocalcaemia (Early), Hypercalcaemia (Recovery phase)
• Compartment Syndrome: Rare

Management:

• Aggressive IV fluids: 3-6 L/day (or more). Target urine output > 200 ml/h.
• Monitor: CK, Renal function, Electrolytes (Every 6-12 hours initially)
• Urinary alkalinisation: Sodium bicarbonate to maintain urine pH > 6.5 (Controversial, May reduce myoglobin precipitation)
• Treat hyperkalaemia: Insulin-dextrose, Calcium gluconate (Cardiac protection), Salbutamol, Sodium bicarbonate, RRT if refractory
• Renal Replacement Therapy: If oliguric AKI or severe hyperkalaemia

Disseminated Intravascular Coagulation (DIC)

Mechanism: Tissue injury → Activation of coagulation cascade → Consumption of clotting factors and platelets → Bleeding + Thrombosis

Features:

• Prolonged PT, APTT
• Low Fibrinogen
• Elevated D-dimer
• Thrombocytopaenia
• Bleeding (Petechiae, Purpura, GI bleeding, Haematuria)
• Thrombosis (Rare)

Management:

• Treat underlying cause (SS/NMS)
• Supportive care: Replace clotting factors (FFP), Platelets, Cryoprecipitate (if fibrinogen less than 1.0 g/L)
• Avoid heparin (unless thrombosis predominates)

Acute Respiratory Distress Syndrome (ARDS)

Mechanism: Severe systemic inflammation → Pulmonary capillary leak → Non-cardiogenic pulmonary oedema

Features:

• Bilateral infiltrates on CXR
• PaO2/FiO2 ratio less than 300 (Mild), less than 200 (Moderate), less than 100 (Severe)
• Respiratory failure

Management:

• Mechanical ventilation: Lung-protective strategies (Low tidal volume 6 ml/kg IBW, Plateau pressure less than 30 cmH2O, PEEP)
• Prone positioning (If severe)
• Conservative fluid management (After initial resuscitation)

Seizures

More common in SS than NMS

Management:

• Benzodiazepines: Lorazepam 4mg IV, Diazepam 10mg IV
• Refractory seizures: Phenytoin, Levetiracetam, Propofol infusion
• Intubation if recurrent seizures

Multi-Organ Failure

End-stage complication of untreated or severe SS/NMS

Features:

• AKI, Hepatic failure (Elevated bilirubin, Transaminases, Coagulopathy), Cardiac failure, ARDS, DIC

Management:

• Organ support: RRT (Renal), Mechanical ventilation (Respiratory), Vasopressors (Cardiovascular)
• ICU care

Prognosis: High mortality (> 50% in multi-organ failure)

---

12. Prognostic Factors

Serotonin Syndrome

Favourable Prognosis:

• Early recognition and drug cessation
• Mild-moderate severity (Temperature less than 40°C)
• Prompt supportive care
• Short-acting serotonergic agents

Poor Prognosis:

• Temperature > 40°C for prolonged period (> 6 hours)
• Severe rigidity (Severe SS can have hypertonia)
• Delayed diagnosis (> 24 hours)
• Rhabdomyolysis with CK > 15,000
• Multi-organ failure
• Elderly or multiple comorbidities

Overall Mortality: less than 5% with treatment. Higher (> 10%) in severe cases with hyperthermia > 40°C.

Neuroleptic Malignant Syndrome

Favourable Prognosis:

• Early diagnosis
• Prompt cessation of antipsychotic
• ICU supportive care
• Atypical antipsychotic (vs typical)

Poor Prognosis: [7]

• Temperature > 40°C
• CK > 15,000 U/L
• Acute renal failure
• Depot antipsychotic (Prolonged duration)
• Delayed diagnosis (> 48 hours)
• Age > 40 years

Overall Mortality: 5-10% with modern ICU care (Previously 20-30%)

---

13. Examination Focus: High-Yield Points

MRCP/FRACP (Medicine)

Common Exam Scenarios:

1. PACES Station 5 (Brief Clinical Consultation): Patient on multiple medications presents with confusion and fever. Identify SS from drug history.
2. Written Exam (SBA): Differentiate SS from NMS based on clinical vignette (Clonus vs Rigidity, Onset timing).
3. Data Interpretation: Given drug list + clinical features + CK level → Diagnose SS or NMS.

Key Exam Points:

• Hunter Criteria: Know the 5 diagnostic criteria. Clonus is key.
• Drug Interactions: SSRI + MAOI, SSRI + Tramadol, Linezolid + SSRI
• Fluoxetine washout: 5 weeks (not 2 weeks)
• Management Priorities: Stop drug > Supportive care > Specific antidote
• Cyproheptadine dosing: 12mg loading, 2mg Q2H, Max 32mg/day
• Avoid antipyretics: Ineffective in both conditions

MRCS/FRCS (Surgery)

Surgical Relevance:

1. Perioperative NMS: Patient on antipsychotics → Post-op rigidity and fever → Differential (NMS vs Malignant hyperthermia vs Sepsis)
2. Methylene Blue: Used in surgery (Parathyroid identification, Fistula mapping). MAO-A inhibitor → Risk of SS if patient on SSRIs. [22]
3. Linezolid: Used for surgical infections (MRSA). Risk of SS with SSRIs.

Key Exam Points:

• Malignant Hyperthermia vs NMS: Onset (Intraoperative vs Days), Trigger (Volatile anaesthetics/Succinylcholine vs Antipsychotics), Family history (MH), Dantrolene is treatment for both
• Methylene Blue caution: Ask about SSRI use before administering
• Succinylcholine contraindication: In suspected NMS/MH (Risk of hyperkalaemia)

MRCOG/FRANZCOG (Obstetrics & Gynaecology)

Obstetric Relevance:

1. SSRIs in pregnancy: Common for antenatal/postnatal depression
2. Neonatal effects: Withdrawal vs Serotonin toxicity in neonate

Key Exam Points:

• Management of SS in pregnancy: Supportive care safe. Cyproheptadine if severe (benefits vs risks).
• Neonatal monitoring: Observe for jitteriness, tremor if maternal SSRI use

MRCEM (Emergency Medicine)

ED Presentations:

1. Undifferentiated fever + confusion: Consider SS/NMS in differential
2. "Sepsis" that doesn't respond to antibiotics
3. Overdose: SSRI overdose → SS

Key Exam Points:

• Rapid assessment: Drug history, Neuromuscular exam (Clonus vs Rigidity)
• Hunter Criteria: Apply in ED
• Initial management: Stop drug, Supportive care, Cooling, Benzodiazepines
• Disposition: Admit moderate-severe cases to HDU/ICU
• Avoid antipsychotics for agitation in unclear fever syndromes

MRCPsych (Psychiatry)

Psychiatric Relevance:

1. Polypharmacy in treatment-resistant depression: SSRI + augmentation strategies
2. Switching antidepressants: Washout periods (Especially Fluoxetine → MAOI)
3. Antipsychotic initiation: Risk of NMS
4. Restarting antipsychotic after NMS: When? Which agent?

Key Exam Points:

• MAOI washout periods: Fluoxetine 5 weeks, Others 2 weeks
• NMS re-challenge risk: 15-30%
• Antipsychotic choice after NMS: Quetiapine or Clozapine (lower risk)
• ECT for refractory NMS: Evidence-based, Safe
• Malignant Catatonia vs NMS: May be indistinguishable. Both respond to ECT.

---

14. Viva Voce Questions and Model Answers

Question 1: "How do you differentiate Serotonin Syndrome from Neuroleptic Malignant Syndrome?"

Model Answer:

"Both are life-threatening hyperthermic syndromes but differ in aetiology, neuromuscular findings, and time course.

Aetiology: SS results from excess serotonergic activity, typically from SSRI combinations or overdose. NMS results from dopamine D2 receptor blockade by antipsychotics or dopamine agonist withdrawal.

Neuromuscular Examination: This is key to differentiation. SS features hyperreflexia and clonus, particularly in the lower limbs. Clonus can be spontaneous, inducible, or ocular. NMS features lead-pipe rigidity without clonus, with bradykinesia and extrapyramidal features.

Time Course: SS develops rapidly, within hours (most cases within 6-24 hours) of drug initiation or dose change. NMS develops slowly, over days (typically 1-3 days, up to 2 weeks).

Laboratory: Both can have elevated CK, but NMS typically has markedly elevated CK (often > 10,000), leucocytosis, and low serum iron.

Management: Both require immediate drug cessation and supportive care. Specific treatment: Cyproheptadine for SS, Dantrolene ± Bromocriptine for NMS."

Question 2: "A patient on an SSRI requires tramadol for pain. What would you advise?"

Model Answer:

"I would advise against this combination due to significant risk of serotonin syndrome.

Tramadol is a dual-mechanism analgesic: it's a mu-opioid receptor agonist AND a serotonin-noradrenaline reuptake inhibitor (SNRI). When combined with an SSRI, there is additive serotonergic activity leading to risk of SS.

Alternatives: I would recommend:

1. Non-serotonergic opioids: Morphine, Oxycodone, Codeine (These lack SNRI activity)
2. Non-opioid analgesics: Paracetamol, NSAIDs (if not contraindicated)
3. Adjuvants: Neuropathic agents like Gabapentin or Pregabalin if neuropathic pain

If tramadol is absolutely essential and there are no alternatives, I would:

• Educate the patient about symptoms of SS (Confusion, Tremor, Sweating, Rapid heartbeat)
• Use the lowest effective dose
• Close monitoring in first 24-48 hours
• Provide clear instructions to stop tramadol and seek help if symptoms develop

However, the safest approach is to avoid the combination entirely."

Question 3: "What are the Hunter Serotonin Toxicity Criteria and why are they important?"

Model Answer:

"The Hunter Criteria are the most validated diagnostic criteria for Serotonin Syndrome, published by Dunkley et al in 2003. They have sensitivity of 84% and specificity of 97%, superior to the older Sternbach criteria.

Criteria: In the presence of a serotonergic agent, diagnosis requires ONE of:

1. Spontaneous clonus
2. Inducible clonus AND (Agitation OR Diaphoresis)
3. Ocular clonus AND (Agitation OR Diaphoresis)
4. Tremor AND Hyperreflexia
5. Hypertonia AND Temperature > 38°C AND (Ocular OR Inducible clonus)

Importance: These criteria emphasise neuromuscular findings, particularly clonus, which is the most specific feature of SS. They provide a standardised, bedside clinical tool for diagnosis, which is critical because:

1. SS is a clinical diagnosis (no specific lab test)
2. Early recognition is essential to prevent progression to severe toxicity
3. Accurate diagnosis differentiates SS from NMS, sepsis, and other hyperthermic syndromes
4. They are practical for emergency settings

The criteria have been validated in ED and toxicology settings and should be routinely applied when SS is suspected."

Question 4: "Why are antipyretics ineffective in Serotonin Syndrome and NMS?"

Model Answer:

"Antipyretics like paracetamol and NSAIDs are ineffective because the mechanism of hyperthermia in SS and NMS is fundamentally different from fever.

Normal Fever: Pyrogens (e.g., from infection) → Hypothalamic thermoregulatory centre → Increased prostaglandin E2 synthesis → Hypothalamic set-point raised. Antipyretics work by inhibiting prostaglandin synthesis, lowering the set-point.

SS/NMS Hyperthermia: The hypothalamic set-point is normal. Hyperthermia results from:

1. SS: Increased muscle activity (Hyperreflexia, Clonus, Tremor, Myoclonus) → Heat generation exceeds dissipation
2. NMS: Muscle rigidity generates heat + Dopamine blockade in hypothalamus impairs heat dissipation

Since the set-point is normal and hyperthermia is due to peripheral heat generation and/or impaired heat dissipation, antipyretics targeting hypothalamic prostaglandins are ineffective.

Correct Management: Active cooling (Ice packs, Cooling blankets, Evaporative cooling) + Reduce heat generation:

• SS: Benzodiazepines (Reduce muscle activity)
• NMS: Dantrolene (Muscle relaxant) + Benzodiazepines
• Both: Neuromuscular paralysis with non-depolarising agents if severe (Abolishes all muscle-generated heat)

This is a critical point for exams and clinical practice."

Question 5: "A patient develops NMS. When and how would you restart an antipsychotic if needed?"

Model Answer:

"This is a challenging clinical scenario requiring careful risk-benefit analysis.

Timing: Wait at least 2 weeks after full resolution of NMS, ideally 4-6 weeks. This allows:

1. Complete drug clearance (especially if depot antipsychotic)
2. Recovery of dopaminergic function
3. Resolution of all clinical features and normalisation of CK

Risk: Recurrence rate is 15-30% if antipsychotic reintroduced, especially if:

• Same agent used
• Reintroduction too early
• Rapid dose escalation

Selection of Agent:

1. Avoid the original causative agent
2. Prefer low-risk atypical antipsychotics: Quetiapine or Clozapine (Lowest reported NMS incidence)
3. Avoid high-risk agents: Haloperidol, Fluphenazine, Depot formulations

Dosing Strategy:

1. Start low: Use the lowest possible dose
2. Go slow: Increase very gradually (Weekly increments)
3. Monitor closely: Review every 1-2 weeks initially

Monitoring:

• Clinical: Temperature, Rigidity, Mental status
• Laboratory: Weekly CK for first month
• Patient education: Recognise early warning signs (Fever, Stiffness)

Alternatives to Consider First:

1. ECT: Safe and effective for schizophrenia, mania, catatonia
2. High-dose Benzodiazepines: For agitation/catatonia
3. Mood stabilisers: Lithium, Valproate (for bipolar disorder)
4. Psychological therapies: CBT

Key Principle: Only restart if psychiatric indication is compelling and alternatives have failed. Always obtain informed consent and document the decision-making process."

---

15. Patient and Layperson Explanation

What are Serotonin Syndrome and Neuroleptic Malignant Syndrome?

These are rare but serious reactions to certain medications. They can cause high fever, confusion, and muscle problems.

Serotonin Syndrome happens when there is too much serotonin (a brain chemical) in your body. This is usually caused by taking certain antidepressants, painkillers (like tramadol), or combinations of these medications.

Neuroleptic Malignant Syndrome is a rare reaction to antipsychotic medications (used for mental health conditions like schizophrenia or severe anxiety). It can also happen if medications for Parkinson's disease are stopped suddenly.

What are the symptoms?

Both conditions can cause:

• High temperature (fever) – often above 38°C, sometimes very high (40°C or more)
• Fast heartbeat
• Sweating (or sometimes dry skin)
• Confusion or agitation
• Muscle problems – stiffness, shaking, or twitching

How to tell them apart:

• Serotonin Syndrome: Muscle twitching, jerking movements, tremors. Symptoms develop quickly (within hours).
• Neuroleptic Malignant Syndrome: Muscle stiffness and rigidity (like the muscles are frozen). Symptoms develop slowly (over days).

What should I do if I think I or someone has this?

This is a medical emergency.

1. Call 999 or go to A&E immediately
2. Bring a list of ALL medications (including over-the-counter medicines, herbal supplements, and recreational drugs)
3. Tell the doctor:
   • What medications you take
   • If you recently started a new medication or changed the dose
   • When symptoms started

How is it treated?

1. Stop the medication that caused it
2. Cooling measures (ice packs, cooling blankets) if you have a high fever
3. Fluids through a drip (to prevent kidney damage)
4. Medications to calm agitation (usually benzodiazepines like diazepam)
5. Sometimes specific medications to reverse the effects:
   • For Serotonin Syndrome: A medication called cyproheptadine
   • For Neuroleptic Malignant Syndrome: Medications called dantrolene or bromocriptine
6. Monitoring in hospital (sometimes in intensive care if severe)

Will I recover?

Yes, most people recover fully if the condition is recognised and treated quickly.

• Serotonin Syndrome: Usually improves within 24-72 hours after stopping the medication
• Neuroleptic Malignant Syndrome: Takes longer, usually 1-2 weeks to recover

Without treatment, both conditions can be life-threatening.

How can I prevent this?

1. Tell ALL your doctors (GP, hospital doctors, dentist) about every medication you take, including:

   • Prescription medications
   • Over-the-counter medicines (like cough syrups)
   • Herbal supplements (like St John's Wort)
   • Recreational drugs

2. Ask about drug interactions before starting a new medication

3. Never stop or change psychiatric medications suddenly without talking to your doctor

4. Seek help early if you feel unwell after starting a new medication

Questions to ask your doctor

• "Are any of my medications likely to interact?"
• "What symptoms should I watch out for?"
• "What should I do if I develop a high fever or feel confused?"
• "Can I take over-the-counter painkillers with my antidepressant?"

---

16. References

Primary Sources

1. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867. PMID: 15784664.

2. Maitland S, Baker M. Serotonin syndrome. Drug Ther Bull. 2022;60(6):88-91. doi:10.1136/dtb.2021.000032. PMID: 35551099.

3. Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome - A focused review. Basic Clin Pharmacol Toxicol. 2023;133(2):124-129. doi:10.1111/bcpt.13912. PMID: 37309284.

4. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109. PMID: 12925718.

5. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-876. doi:10.1176/ajp.2007.164.6.870. PMID: 17541044.

6. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24(2):155-162. PMID: 22563571.

7. Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11(1):R4. doi:10.1186/cc5148. PMID: 17222333.

8. Uddin MF, Alweis R, Shah SR, et al. Controversies in Serotonin Syndrome Diagnosis and Management: A Review. J Clin Diagn Res. 2017;11(9):OE05-OE07. doi:10.7860/JCDR/2017/29473.10696. PMID: 29207768.

9. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-441. doi:10.1093/bja/aei210. PMID: 16051647.

10. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361-365. PMID: 17874986.

11. Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother. 2016;50(11):973-981. doi:10.1177/1060028016657553. PMID: 27340146.

12. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202. PMID: 8093494.

13. Oechsner M, Korchounov A. Parkinsonism-hyperpyrexia syndrome: a life-threatening complication of dopaminergic therapy. Mov Disord. 2005;20(11):1528-1529. doi:10.1002/mds.20611. PMID: 16078209.

14. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089-1099. doi:10.1111/j.1526-4610.2010.01691.x. PMID: 20618823.

15. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician. 2015;18(4):395-400. PMID: 26218943.

16. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42(11):1578-1583. doi:10.1086/503839. PMID: 16652315.

17. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. doi:10.1186/s13023-015-0310-1. PMID: 26238698.

18. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33(5):650-659. doi:10.1080/j.1440-1614.1999.00630.x. PMID: 10544986.

19. Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Curr Neuropharmacol. 2015;13(3):395-406. doi:10.2174/1570159x13999150424113345. PMID: 26411766.

20. Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann. 2000;30(5):325-331.

21. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. Int J Tryptophan Res. 2019;12:1178646919873925. doi:10.1177/1178646919873925. PMID: 31548780.

22. Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat. 2017;13:161-175. doi:10.2147/NDT.S118438. PMID: 28176896.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.

---

Document Status: Gold Standard Enhanced Lines: 1,461 Citations: 22 Last Updated: 2026-01-11 Topic: 652/1,071